Literature DB >> 16439518

Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants.

Heather H Cheng1, Maria M Anderson, F Claire Hankenson, Lily Johnston, Chitra V Kotwaliwale, Julie Overbaugh.   

Abstract

Gammaretroviruses, including the subgroups A, B, and C of feline leukemia virus (FeLV), use a multiple-membrane-spanning transport protein as a receptor. In some cases, such as FeLV-T, a nonclassical receptor that includes both a transport protein (Pit1) and a soluble cofactor (FeLIX) is required for entry. To define which regions confer specificity to classical versus nonclassical receptor pathways, we engineered mutations found in either FeLV-A/T or FeLV-T, individually and in combination, into the backbone of the transmissible form of the virus, FeLV-A. The receptor specificities of these viruses were tested by measuring infection and binding to cells expressing the FeLV-A receptor or the FeLV-T receptors. FeLV-A receptor specificity was maintained when changes at amino acid position 6, 7, or 8 of the mature envelope glycoprotein were introduced, although differences in infection efficiency were observed. When these N-terminal mutations were introduced together with a C-terminal 4-amino-acid insertion and an adjacent amino acid change, the resulting viruses acquired FeLV-T receptor specificity. Additionally, a W-->L change at amino acid position 378, although not required, enhanced infectivity for some viruses. Thus, we have found that determinants in the N and C termini of the envelope surface unit can direct entry via the nonclassical FeLV-T receptor pathway. The region that has been defined as the receptor binding domain of gammaretroviral envelope proteins determined entry via the FeLV-A receptor independently of the presence of the N- and C-terminal FeLV-T receptor determinants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439518      PMCID: PMC1367127          DOI: 10.1128/JVI.80.4.1619-1628.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein.

Authors:  D Lavillette; B Boson; S J Russell; F L Cosset
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

3.  Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection.

Authors:  A L Barnett; R A Davey; J M Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2.

Authors:  J Sugai; M Eiden; M M Anderson; N Van Hoeven; C D Meiering; J Overbaugh
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants.

Authors:  A S Lauring; M M Anderson; J Overbaugh
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion.

Authors:  A L Barnett; J M Cunningham
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Functional characterization of the N termini of murine leukemia virus envelope proteins.

Authors:  C W Lu; M J Roth
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses.

Authors:  M M Anderson; A S Lauring; S Robertson; C Dirks; J Overbaugh
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Relationship between SU subdomains that regulate the receptor-mediated transition from the native (fusion-inhibited) to the fusion-active conformation of the murine leukemia virus glycoprotein.

Authors:  Dimitri Lavillette; Alessia Ruggieri; Bertrand Boson; Marielle Maurice; François-Loïc Cosset
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus.

Authors:  Anna L Barnett; David L Wensel; Weihua Li; Deborah Fass; James M Cunningham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  4 in total

1.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.

Authors:  Kathryn S Jones; Kazunori Fugo; Cari Petrow-Sadowski; Ying Huang; Daniel C Bertolette; Ivonne Lisinski; Samuel W Cushman; Steven Jacobson; Francis W Ruscetti
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor.

Authors:  Heather H Cheng; Maria M Anderson; Julie Overbaugh
Journal:  Virology       Date:  2006-10-13       Impact factor: 3.616

3.  Reduced Folate Carrier: an Entry Receptor for a Novel Feline Leukemia Virus Variant.

Authors:  Ariko Miyake; Junna Kawasaki; Ha Ngo; Isaac Makundi; Yutaro Muto; Arshad H Khan; Desmond J Smith; Kazuo Nishigaki
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

4.  Identification of residues outside of the receptor binding domain that influence the infectivity and tropism of porcine endogenous retrovirus.

Authors:  Takele Argaw; Mariel Figueroa; Daniel R Salomon; Carolyn A Wilson
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.